Literature DB >> 14664797

Minimal toxicity of stabilized compacted DNA nanoparticles in the murine lung.

Assem-Galal Ziady1, Christopher R Gedeon, Osman Muhammad, Virginia Stillwell, Sharon M Oette, Tamara L Fink, Will Quan, Tomasz H Kowalczyk, Susannah L Hyatt, Jennifer Payne, Angela Peischl, J E Seng, Robert C Moen, Mark J Cooper, Pamela B Davis.   

Abstract

Nanoparticles containing DNA compacted with poly-l-lysine modified on an N-terminal cysteine with polyethylene glycol can effectively transfect cells of the airway epithelium when applied by the luminal route. To evaluate the toxicity of these nanoparticles, we administered 10 and 100 microg DNA compacted into nanoparticles suspended in normal saline by the intranasal route to mice and determined the pulmonary and systemic responses to this challenge, compared to administration of saline alone, and in some experiments, compared to administration of naked DNA, Escherichia coli genomic DNA, or lipofectin-complexed naked DNA. There was no systemic response to either dose of nanoparticles in serum chemistries, hematologic parameters, serum complement, IL-6, or MIP-2 levels or in the activity, growth, and grooming of the mice. Nanoparticles containing 10 microg DNA induced responses comparable to saline in all measures, including BAL cell counts and differentials and cytokine levels and histology. However, mice dosed with 100 microg DNA in nanoparticles had modest increases in BAL neutrophils 48 and 72 h after dosing, modest increases in BAL IL-6 and KC beginning 24 and 48 h, respectively, after dosing, and, on histology of the lung, a trace to 1+ mononuclear cell infiltrates about the pulmonary veins at 48 h, which were markedly reduced by 10 days and gone by 28 days after dosing. BAL neutrophil and cytokine responses were no greater than those entrained by naked DNA for up to 24 h. However, compared to administration of only 10 microg E. coli genomic DNA, the response to compacted DNA was much less. A low dose of lipofectin-complexed DNA (5 microg DNA) induced the same response as 20-fold higher doses of DNA nanoparticles. These data indicate that DNA nanoparticles have no measurable toxic effect at a dose of 10 microg and a very modest effect, which is not limiting, at a dose of 100 microg, which gives maximal gene expression. This favorable toxicity profile encourages development of stabilized compacted DNA for airway administration.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14664797     DOI: 10.1016/j.ymthe.2003.09.002

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  44 in total

Review 1.  Nanoparticles for retinal gene therapy.

Authors:  Shannon M Conley; Muna I Naash
Journal:  Prog Retin Eye Res       Date:  2010-05-07       Impact factor: 21.198

Review 2.  Gene therapy in clinical medicine.

Authors:  S M Selkirk
Journal:  Postgrad Med J       Date:  2004-10       Impact factor: 2.401

3.  Optimization of hCFTR lung expression in mice using DNA nanoparticles.

Authors:  Linas Padegimas; Tomasz H Kowalczyk; Sam Adams; Chris R Gedeon; Sharon M Oette; Karla Dines; Susannah L Hyatt; Ozge Sesenoglu-Laird; Olena Tyr; Robert C Moen; Mark J Cooper
Journal:  Mol Ther       Date:  2011-09-27       Impact factor: 11.454

Review 4.  Pulmonary applications and toxicity of engineered nanoparticles.

Authors:  Jeffrey W Card; Darryl C Zeldin; James C Bonner; Earle R Nestmann
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2008-07-18       Impact factor: 5.464

5.  Rhodopsin Genomic Loci DNA Nanoparticles Improve Expression and Rescue of Retinal Degeneration in a Model for Retinitis Pigmentosa.

Authors:  Min Zheng; Rajendra N Mitra; Ellen R Weiss; Zongchao Han
Journal:  Mol Ther       Date:  2019-12-14       Impact factor: 11.454

Review 6.  AAV and compacted DNA nanoparticles for the treatment of retinal disorders: challenges and future prospects.

Authors:  Zongchao Han; Shannon M Conley; Muna I Naash
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-05-10       Impact factor: 4.799

7.  DNA nanoparticle-mediated thymulin gene therapy prevents airway remodeling in experimental allergic asthma.

Authors:  Adriana L da Silva; Sabrina V Martini; Soraia C Abreu; Cynthia dos S Samary; Bruno L Diaz; Sandra Fernezlian; Vanessa Karen de Sá; Vera Luiza Capelozzi; Nicholas J Boylan; Rodolfo Gustavo Goya; Jung Soo Suk; Patricia R M Rocco; Justin Hanes; Marcelo M Morales
Journal:  J Control Release       Date:  2014-02-17       Impact factor: 9.776

8.  Gene delivery to mitotic and postmitotic photoreceptors via compacted DNA nanoparticles results in improved phenotype in a mouse model of retinitis pigmentosa.

Authors:  Xue Cai; Shannon M Conley; Zack Nash; Steven J Fliesler; Mark J Cooper; Muna I Naash
Journal:  FASEB J       Date:  2009-12-01       Impact factor: 5.191

9.  Non-covalent ligand conjugation to biotinylated DNA nanoparticles using TAT peptide genetically fused to monovalent streptavidin.

Authors:  Wenchao Sun; David Fletcher; Rolf Christiaan van Heeckeren; Pamela B Davis
Journal:  J Drug Target       Date:  2012-09       Impact factor: 5.121

Review 10.  Barriers to inhaled gene therapy of obstructive lung diseases: A review.

Authors:  Namho Kim; Gregg A Duncan; Justin Hanes; Jung Soo Suk
Journal:  J Control Release       Date:  2016-05-16       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.